What questions can CiteAb antibody market data help you answer?

If you’ve been following our work here at CiteAb for a while now you’ll know we periodically release snapshots from our data which give insight to the performance of various aspects of the global antibody market.

data_visualization[1]We market datasets allow suppliers to answer key questions that support the growth and development of their businesses – many of the largest antibody suppliers are already using CiteAb data to make key business decisions.

For example, today we are releasing a snapshot of data which shows the top 20,000 antibodies currently on the market, providing key data for suppliers to spot gaps in their antibody portfolio. You can get some of this data for free today if you sign up below!

Dr Andrew Chalmers, founder of CiteAb, said: “Today’s data shows how a company’s products are faring compared to its competitors, which is crucial to inform the setting of prices and in deciding on marketing priorities.”

Just some of the other questions that can be informed with help from CiteAb data include:
– Which antibodies should we be raising or licensing?
– Are there countries where bioscience research is growing that I should expand into?
– Are there particular research institutions I should market certain products to?
– Which research groups would be interested in our latest antibody?
– Are there particular applications that are becoming increasingly important?
– Am I missing a growth area of the market in my product portfolio?
– How are we performing compared to our closest competitors?
– Is there data on our performance that will reassure our shareholders?
– Who are my competitors selling to?

Our market reports at CiteAb are not based on user surveys or web usage statistics like some available in the sector – they are based on the analysis of hundreds of thousands of antibody citations and provide a quantitative view of the research antibody market and how it’s changing over time. They are currently helping some of the world’s leading antibody manufacturers tackle hundreds of questions such as these every day.

Commenting on the data we’re releasing today, Dr Chalmers said: “The antibody most cited in 2016 is the AKT antibody from Cell Signalling.

“Those of you who saw our CiteAb Antibody Awards results back in January will have noticed that the top antibody then was the Anti-β-Actin antibody from Sigma Aldrich, and this demonstrates how quickly the market can change and how valuable real-time data can be.”

In this latest dataset we see many of the bigger suppliers dominate the top twenty – Cell Signalling Technology, Sigma Aldrich, Abcam, Millipore, Invitrogen Antibodies and Santa Cruz. However just outside the top twenty there are many suppliers represented – Dako, the not-for-profit Developmental Studies Hybridoma Bank (DSHB), BD Biosciences and LI-COR Biosciences.

Dr Chalmers adds: “A secondary antibody from LIi-COR (IRDye® 800CW Goat anti-Rabbit IgG) has made it into the top 100 for the first time, a piece of data that demonstrates to suppliers that the rise of fluorescent western blotting has driven changes in antibody use.”

Today we are making the data for the top twenty most cited antibodies available for free. To obtain your free sample data, discuss a custom dataset or have a specific query you’d like to answer with our data please get in touch and we’d be happy to discuss options with you.

– Matt and the CiteAb team


Subscribe to the CiteAb Newsletter